A registration statement relating to these securities was filed and declared effective August 25, 2000 by the Securities and Exchange Commission. This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the prospectus may be obtained from Hypertension Diagnostics, Inc., Attention: James S. Murphy, Chief Financial Officer, 2915 Waters Road, Suite 108, Eagan, MN 55121-1562.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not predictions of actual future results. Actual results could differ materially from those anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 1999 Annual Report on Form 10-KSB under the caption "Risk Factors", as well as others not now anticipated. These risks and uncertainties include, without limitation, the Company’s ability to receive regulatory approval for its CVProfilor^® DO-2020 CardioVascular Profiling System; the availability of third-party reimbursements; and market acceptance of the Company’s products.

Hypertension Diagnostics and CVProfilor^® are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Contact: James S. Murphy, Chief Financial Officer